´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ 2022³â Á¦ 7ȸ Á¶Ç÷¸ð¼¼Æ÷ÀÌ½Ä ¾ÆÄ«µ¥¹Ì : 2022-03-05±³À°ÀÏÀÚ : 2022-03-05
±³À°Àå¼Ò : ¶ó¸¶´ÙÇöóÀÚ ±¤ÁÖÈ£ÅÚ
±³À°ÁÖÁ¦ :
2022³â Á¦ 7ȸ Á¶Ç÷¸ð¼¼Æ÷ÀÌ½Ä ¾ÆÄ«µ¥¹ÌÁÖÃÖ±â°ü : ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
bmt@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
±¤ÁÖ±¤¿ª½Ã±³À°½Ã°£ : 6 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-05 ´ë¿¬È¸Àå 09:10~09:50 Bone marrow engraftment: histopathology of hematopoietic reconstitution following HSCT(hematopoietic stem cell transplantation) ¼ÛÀÍÂù(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 03-05 ´ë¿¬È¸Àå 09:50~10:30 The role of conditioning intensity in HCT(hematocrit) Á¶º´½Ä(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-05 ´ë¿¬È¸Àå 11:00~11:40 CAR-T cell therapy versus allogeneic HCT(hematocrit) ±è¼®Áø(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03-05 ´ë¿¬È¸Àå 11:40~12:20 MRD monitoring using NGS after HCT(hematocrit) in patient with lymphoma/MM ¾È¾Æ¸®(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-05 ´ë¿¬È¸Àå 13:30~14:10 GVHD(graft-versus-host disease) prophylaxis: ATG(antithymocyte globulin) versus PTCy(Post-Transplant Cyclophosphamide) ¹Ú¿ë(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03-05 ´ë¿¬È¸Àå 14:10~14:50 First and second line systemic management of acute GVHD(graft-versus-host disease) ÃÖÀ±¼÷(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03-05 ´ë¿¬È¸Àå 14:50~15:30 How to prevent/treat relapse following allogeneic HCT(hematocrit) ½Åµ¿¿±(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-05 ´ë¿¬È¸Àå 16:00~16:40 Care of immediate post-transplant period À¯ÄèÇÑ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 03-05 ´ë¿¬È¸Àå 16:40~17:20 Survivorship, one year after HSCT(hematopoietic stem cell transplantation) and beyond ¾È¼¿¬(Àü³²ÀÇ´ë)